Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
January 06 2021 - 4:10PM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, announced today that Chief Financial Officer Sung Lee is
leaving the Company to pursue a new opportunity overseas. Mr. Lee’s
last day of employment will be February 1, 2021.
“Sung has contributed significantly to Sangamo’s evolution,
helping us build a strong cash position to advance proprietary
medicines for patients in need as we begin a year with several
potential catalysts,” said Sandy Macrae, Chief Executive Officer of
Sangamo. “I have deep appreciation for the integrity and leadership
Sung brought to Sangamo. The management team and board of directors
at Sangamo join me in wishing him the very best as we initiate our
search for a new CFO.”
“It has been a privilege to work with Sandy and the Sangamo team
to advance the innovative field of genomic medicine, and I believe
the company is well positioned to execute on its strategy,” said
Mr. Lee.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, ex vivo gene-edited cell
therapy, and in vivo genome editing and genome regulation. For more
information about Sangamo, visit www.sangamo.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210106005808/en/
Investor Relations & Media
Inquiries Aron Feingold 628.252.7494
afeingold@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Apr 2023 to Apr 2024